Design, synthesis and bioactivity evaluation of the combination of evodiamine and erlotinib linked by indolequinone

Compared with single-targeted therapy, the design and synthesis of heterozygous molecules is still a significant challenge for the discovery of antitumor drugs. Quinone oxidoreductase-1 (NQO1) is a potential target for selective Cancer therapy due to its overexpression in many Cancer cells and its unique bioredox properties. Based on the principle of combinatorial drug design, we successfully synthesized a new hybrid molecules 13 with an indolequinone structure. We found that the synthesized compounds exhibited much higher cytotoxicity against the tested Cancer cells than free drugs. Further mechanism studies confirmed that compound 13 induced cell Apoptosis was achieved by regulating p53-dependent mitochondrial pathway and cell cycle arrest at the G0/G1 phase.

Biological activity; Erlotinib; Evodiamine; Indolequinone structure; Quinone oxidoreductase-1.